Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Cell therapy: A powerful treatment for cancer patients

Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.

24 Feb 2014

Researchers find new drug compound that treats laboratory mice with congenital heart disease

Congenital heart disease is the most common form of birth defect, affecting one out of every 125 babies, according to the National Institutes of Health. Researchers from the University of Missouri recently found success using a drug to treat laboratory mice with one form of congenital heart disease, hypertrophic cardiomyopathy - a weakening of the heart caused by abnormally thick muscle.

23 Feb 2014

Non-coding RNAs linked to cancer and cancer survival

Several scientists, including one at Simon Fraser University, have made a discovery that strongly links a little understood molecule, which is similar to DNA, to cancer and cancer survival.

21 Feb 2014

Study on Zebrafish neurons could lead to better understanding of birth defects in humans

The zebrafish, a tropical freshwater fish similar to a minnow and native to the southeastern Himalayan region, is well established as a key tool for researchers studying human diseases, including brain disorders.

21 Feb 2014

Ulcerative colitis patients not satisfied with current treatments according to new study

Patients with a serious type of inflammatory bowel disease, ulcerative colitis, are not satisfied with their current treatments and the majority do not have their disease under control, according to new research released today at the 9th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. The majority (87.2 per cent) of the 250 patients with moderate to severe ulcerative colitis who were being treated with standard therapies failed to achieve control of their disease – defined either as going into remission or not having needed to use corticosteroid medications in the previous two months.1

21 Feb 2014

Genetic study reveals 11 new genetic signals are associated with blood pressure levels

A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.

21 Feb 2014

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor oncentrate in patients with frequent hereditary angioedema attacks (NCT01912456).

20 Feb 2014

Study finds Cyclin A2 protein induces cardiac regeneration after myocardial infarction

After a heart attack, there is often permanent damage to a portion of the heart. This happens, in part, because cardiac muscle cells are terminally differentiated and cannot proliferate after blood flow is blocked off to the heart.

20 Feb 2014

Researchers propose new treatment to prevent mucositis in cancer patients

Experimental work pointing to a therapy for alleviating mucositis -- a common, severe side effect of chemotherapy and irradiation of cancer patients or patients prepared for bone marrow transplantation - has been achieved by an international team of researchers from the US and Israel headed by scientists at the Hebrew University of Jerusalem.

20 Feb 2014

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

20 Feb 2014

Scientists receive 2014 Dan David Prize for exceptional excellence in sciences, arts and humanities

Pulitzer Prize-winning Holocaust historian Prof. Saul Friedlander and artificial intelligence pioneer Prof. Marvin Minsky are among the winners of the 2014 Dan David Prize, which annually bestows three awards of $1 million each.

20 Feb 2014

UPV/EHU researchers develop method for diagnosis, prognosis of cutaneous melanoma

UPV/EHU researchers have developed a method for the diagnosis and prognosis of cutaneous melanoma, the type of skin cancer with the highest mortality rate.This method will help not only in the more effective early detection of this cancer, but also in the development of more personalised treatments.

20 Feb 2014

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Oncologists and cancer patients could improve the results of drug therapies by making real-time decisions about treatment options using an innovation developed in Purdue University's College of Pharmacy.

20 Feb 2014

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually.

20 Feb 2014

Deficiency in SNX27 explains learning impairment in Down's syndrome

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have identified the precise role of the protein, SNX27, in the pathway leading to memory and learning impairment.

20 Feb 2014

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

PBL Assay Science announces a licensing agreement with HumanZyme, Inc. (Chicago, USA) to expand reagent offerings. The agreement allows PBL to provide ~50 authentic human cell-expressed (HCE) cytokines and growth factors directly to scientists worldwide.

From PBL Assay Science 20 Feb 2014

New biologic drug to prevent growth of ovarian cancer cells

Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.

20 Feb 2014

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.

19 Feb 2014

Researchers develop method for diagnosis and prognosis of cutaneous melanoma

19 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

Protein News and Research

Further Reading

Cell therapy: A powerful treatment for cancer patients

Researchers find new drug compound that treats laboratory mice with congenital heart disease

Non-coding RNAs linked to cancer and cancer survival

Study on Zebrafish neurons could lead to better understanding of birth defects in humans

Ulcerative colitis patients not satisfied with current treatments according to new study

Genetic study reveals 11 new genetic signals are associated with blood pressure levels

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

Study finds Cyclin A2 protein induces cardiac regeneration after myocardial infarction

Researchers propose new treatment to prevent mucositis in cancer patients

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Scientists receive 2014 Dan David Prize for exceptional excellence in sciences, arts and humanities

UPV/EHU researchers develop method for diagnosis, prognosis of cutaneous melanoma

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

Deficiency in SNX27 explains learning impairment in Down's syndrome

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

New biologic drug to prevent growth of ovarian cancer cells

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Researchers develop method for diagnosis and prognosis of cutaneous melanoma

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

Editorial Focus eBook - Proteomics eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics